We are live on ! Find out more
BNTX icon

BioNTech

225 hedge funds and large institutions have $3.25B invested in BioNTech in 2021 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 71 increasing their positions, 47 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 38

83% more capital invested

Capital invested by funds: $1.77B → $3.25B (+$1.47B)

51% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 47

16% more funds holding

Funds holding: 194225 (+31)

3.4% more ownership

Funds ownership: 9.13%12.53% (+3.4%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

23% less call options, than puts

Call options by funds: $301M | Put options by funds: $391M

Holders
225
Holders Change
+31
Holders Change %
+15.98%
% of All Funds
3.95%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
70
Increased
71
Reduced
47
Closed
38
Calls
$301M
Puts
$391M
Net Calls
-$90.4M
Net Calls Change
-$78.8M

BNTX Hedge Fund Activity: Q1 2021 in Review

225 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q1 2021, worth a combined $3.25B — up 83% from $1.77B a quarter earlier.

Buyers outnumbered sellers: 70 funds opened new BNTX positions and 38 closed out — a net gain of 32 holders — while 71 added to existing stakes and 47 trimmed.

The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $716M. The largest seller was Fidelity Investments, cutting an estimated $122M.

  • 225 institutional investors held BioNTech (BNTX) as of Q1 2021, up from 194 in Q4 2020.
  • Funds reported $3.25B of BioNTech stock for Q1 2021, up 83% quarter-over-quarter.
  • 70 funds opened new BioNTech positions in Q1 2021 and 38 closed out, a net change of +32 holders.
  • The largest BioNTech buyer in Q1 2021 was Baillie Gifford & Co, an estimated $716M added.
  • The largest BioNTech seller in Q1 2021 was Fidelity Investments, an estimated $122M sold.

Based on aggregated 13F filings for Q1 2021.